Table 2 Univariate analysis of cardiotoxicity associated with targeted therapy.
From: Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer
Characteristic | No cardiotoxicity n (%) | Cardiotoxicity n (%) | χ2 | P |
|---|---|---|---|---|
Age, years | 9.834 | 0.002* | ||
< 60 | 283 (87.1) | 42 (12.9) | ||
≥ 60 | 70 (73.7) | 25 (26.3) | ||
BMI (kg/m2) | 2.100 | 0.147 | ||
< 24 | 171 (86.8) | 26 (13.2) | ||
≥ 24 | 182 (81.6) | 41 (18.4) | ||
Menopausal status | 3.144 | 0.076 | ||
Premenopause | 168 (87.5) | 24 (12.5) | ||
Postmenopausal | 185 (81.1) | 43 (18.9) | ||
Hypertension | 8.709 | 0.003* | ||
Yes | 73 (74.5) | 25 (25.5) | ||
No | 280 (87.0) | 42 (13.0) | ||
Diabetes | 0.081 | 0.776 | ||
Yes | 43 (82.7) | 9 (17.3) | ||
No | 310 (84.2) | 58 (15.8) | ||
CAD | 14.702 | < 0.001* | ||
Yes | 45 (68.2) | 21 (31.8) | ||
No | 308 (87.0) | 46 (13.0) | ||
Smoking | 0.001 | 0.977 | ||
Yes | 32 (84.2) | 6 (15.8) | ||
No | 321 (84.0) | 61 (16.0) | ||
Invasive ductal carcinoma | 0.046 | 0.831 | ||
Yes | 335 (84.0) | 64 (16.0) | ||
No | 18 (85.7) | 3 (14.3) | ||
Histilogical grade | 0.003 | 0.998 | ||
I | 31 (83.8) | 6 (16.2) | ||
II | 254 (84.1) | 48 (15.9) | ||
III | 68 (84.0) | 13 (16.0) | ||
T stage | 1.762 | 0.184 | ||
T1–2 | 263 (82.7) | 55 (17.3) | ||
T3–4 | 90 (88.2) | 12 (11.8) | ||
N stage | 0.210 | 0.647 | ||
N0–1 | 137 (83.0) | 28 (17.0) | ||
N2–3 | 216 (84.7) | 39 (15.3) | ||
Tumor stage | 0.787 | 0.675 | ||
I | 44 (88.0) | 6 (12.0) | ||
II | 242 (83.2) | 49 (16.8) | ||
III | 67 (84.8) | 12 (15.2) | ||
HR status | 0.299 | 0.585 | ||
Positive | 285 (83.6) | 56 (16.4) | ||
Negative | 68 (86.1) | 11 (13.9) | ||
Ki67 | 3.096 | 0.078 | ||
< 20% | 45 (76.3) | 14 (23.7) | ||
≥ 20% | 308 (85.3) | 53 (14.7) | ||
Neoadjuvant therapy | 1.464 | 0.226 | ||
Yes | 99 (87.6) | 14 (12.4) | ||
No | 254 (82.7) | 53 (17.3) | ||
Surgery type | 0.482 | 0.488 | ||
Breast conserving | 42 (87.5) | 6 (12.5) | ||
Mastectomy | 311 (83.6) | 61 (16.4) | ||
Anthracyclines | 5.548 | 0.018* | ||
Yes | 239 (81.3) | 55 (18.7) | ||
No | 114 (90.5) | 12 (9.5) | ||
Targeted therapy | 0.976 | 0.323 | ||
H | 197 (85.7) | 33 (14.3) | ||
HP | 156 (82.1) | 34 (17.9) | ||
Radiotherapy | 0.358 | 0.550 | ||
Yes | 301 (83.6) | 59 (16.4) | ||
No | 52 (86.7) | 8 (13.3) | ||
Radiotherapy position | 8.978 | 0.003* | ||
Left chest wall area | 145 (78.0) | 41 (22.0) | ||
Right chest wall area | 156 (89.7) | 18 (12.3) |
